RPG Life Sciences Limited

Total Valuation

RPG Life Sciences Limited carries a market capitalization of 40.00B, placing it among publicly traded companies globally. Its enterprise value stands at 41.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

RPG Life Sciences Limited trades at a trailing price-to-earnings ratio of 22.44.

Enterprise Valuation

On an enterprise value basis, RPG Life Sciences Limited trades at an EV/EBITDA multiple of 30.44 and an EV/FCF ratio of 8,689.36. The EV/Sales ratio of 6.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.44 provides insight into valuation relative to core operating earnings.

Financial Position

RPG Life Sciences Limited maintains a current ratio of 5.85, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, RPG Life Sciences Limited has paid 495.40M in income taxes, reflecting an effective tax rate of 21.32.

Stock Price Statistics

RPG Life Sciences Limited's stock has declined approximately -8.74239% over the past 52 weeks. The 50-day moving average sits at 2,260.91, while the 200-day moving average is 2,180.98.

Income Statement

Over the trailing twelve months, RPG Life Sciences Limited generated 6.57B in revenue and converted that into 1.83B in net income, yielding earnings per share of 110.52. EBITDA reached 1.35B, while operating income came in at 1.35B.

Margins

RPG Life Sciences Limited operates with a gross margin of 66.66, reflecting its pricing power and cost economics. The operating margin of 20.52 and net profit margin of 27.82 provide insight into operational efficiency.

Scores

RPG Life Sciences Limited posts an Altman Z-Score of 36.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.